MX2021013318A - Combination therapies comprising apremilast and tyk2 inhibitors. - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors.

Info

Publication number
MX2021013318A
MX2021013318A MX2021013318A MX2021013318A MX2021013318A MX 2021013318 A MX2021013318 A MX 2021013318A MX 2021013318 A MX2021013318 A MX 2021013318A MX 2021013318 A MX2021013318 A MX 2021013318A MX 2021013318 A MX2021013318 A MX 2021013318A
Authority
MX
Mexico
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
MX2021013318A
Other languages
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021013318A publication Critical patent/MX2021013318A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
MX2021013318A 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors. MX2021013318A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2021013318A true MX2021013318A (en) 2022-01-31

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021013317A MX2021013317A (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.
MX2021013318A MX2021013318A (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021013317A MX2021013317A (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015622A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287665A (en) 2019-04-30 2022-07-01 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
BR112023016590A2 (en) 2021-02-19 2023-11-14 Sudo Biosciences Ltd TYK2 INHIBITORS AND THEIR USES
CA3232812A1 (en) * 2021-09-23 2023-03-30 Ian MacQuarie CATLETT Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CN103635188B (en) * 2011-04-28 2017-03-22 细胞基因公司 Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
PL2797581T3 (en) * 2011-12-27 2020-10-05 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
JP6109192B2 (en) 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Pyridazine amide compounds and their use as SYK inhibitors
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
EP2855451B1 (en) 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
EP4071144A1 (en) * 2012-11-08 2022-10-12 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CA2890935A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
US9872854B2 (en) * 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2941824C (en) 2013-09-03 2020-08-25 Sareum Limited Substituted phenylamino-oxazole-4-carboxylic acid amides as tyk2 kinase inhibitors
AR094537A1 (en) 2013-11-07 2015-08-12 Bristol Myers Squibb Co PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CA2940666C (en) 2014-02-28 2022-08-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3157520B1 (en) * 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
CO2018008799A2 (en) 2016-02-24 2018-09-20 Pfizer Pyrazolo [1,5-a] pyrazin-4-yl derivatives as jak inhibitors
EP3523305B1 (en) 2016-10-07 2021-12-08 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3526222B1 (en) 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN110114357B (en) 2016-10-28 2022-05-31 百时美施贵宝公司 Hetero-bicyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response
JP7012082B2 (en) 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Imidazopyridazine regulator of IL-12, IL-23 and / or IFN-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TWI783978B (en) * 2017-03-08 2022-11-21 美商林伯士拉克許米公司 Tyk2 inhibitors, uses, and methods for production thereof
IL287665A (en) 2019-04-30 2022-07-01 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
WO2020222773A1 (en) 2020-11-05
CN114206333A (en) 2022-03-18
EP3962476A1 (en) 2022-03-09
WO2020223431A1 (en) 2020-11-05
SG11202112043PA (en) 2021-11-29
CL2021002847A1 (en) 2022-07-22
BR112021021826A8 (en) 2022-06-21
CO2021015622A2 (en) 2022-02-28
AU2020266143A1 (en) 2021-12-02
JP2022537877A (en) 2022-08-31
IL287665A (en) 2022-07-01
IL287670A (en) 2021-12-01
MA55799A (en) 2022-03-09
BR112021021809A2 (en) 2022-01-04
SG11202112018YA (en) 2021-11-29
CA3138686A1 (en) 2020-11-05
JP2022537878A (en) 2022-08-31
MX2021013317A (en) 2022-01-18
CO2021015614A2 (en) 2021-12-10
CN114269336A (en) 2022-04-01
CA3138473A1 (en) 2020-11-05
KR20220002488A (en) 2022-01-06
BR112021021826A2 (en) 2022-01-04
EP3962475A1 (en) 2022-03-09
JP7453251B2 (en) 2024-03-19
KR20220002489A (en) 2022-01-06
AU2019443366A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2021013318A (en) Combination therapies comprising apremilast and tyk2 inhibitors.
JOP20220008A1 (en) Parp1 inhibitors
MX2021002804A (en) Combination therapies.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
CR20210209A (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2018005600A (en) Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
CR20220325A (en) Fluoroalkyl-oxadiazoles and uses thereof
MX2021002805A (en) Combination therapies.
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
CR20220280A (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
AR116024A1 (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
WO2022261467A9 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2020011912A (en) Combination therapy for treatment of hcv.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.
CL2021002846A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MX2023002210A (en) Combination therapies with olig2 inhibitors.